518 filings
8-K
QLGN
Qualigen Therapeutics Inc
27 Feb 24
Entry into a Material Definitive Agreement
7:00am
8-K
QLGN
Qualigen Therapeutics Inc
22 Feb 24
Entry into a Material Definitive Agreement
4:10pm
8-K
QLGN
Qualigen Therapeutics Inc
7 Dec 23
Entry into a Material Definitive Agreement
4:15pm
8-K
QLGN
Qualigen Therapeutics Inc
22 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
QLGN
Qualigen Therapeutics Inc
14 Nov 23
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
5:10pm
8-K
frfle4qr
8 Nov 23
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
2:16pm
8-K
fl70cv7mftc j9n
17 Oct 23
Regulation FD Disclosure
8:30am
424B3
6486l riqcl3auv8
29 Sep 23
Prospectus supplement
4:30pm
8-K
a0gbm5nvdlhl8sk
28 Sep 23
Entry into a Material Definitive Agreement
4:15pm
EFFECT
ehdx38a0w4wqslf9rjzx
8 Sep 23
Notice of effectiveness
12:15am
POS AM
lwu2i6qdqfgfmabwh5
1 Sep 23
Prospectus update (post-effective amendment)
4:15pm
8-K
qkq wrhz71m57ka4r
15 Aug 23
Results of Operations and Financial Condition
10:04am
8-K
ez58o2xt
4 Aug 23
Departure of Directors or Certain Officers
4:30pm
8-K
wnpd0cwf 32phwf7fx
1 Aug 23
Regulation FD Disclosure
8:35am
8-K
ohcm 2ujachvoyshme
26 Jul 23
Entry into a Material Definitive Agreement
5:25pm
8-K
y3sxp8
13 Jul 23
Submission of Matters to a Vote of Security Holders
5:29pm